Marquez-Curtis Leah A, Turner A Robert, Larratt Loree M, Letcher Brenda, Lee Siow F, Janowska-Wieczorek Anna
Canadian Blood Services, University of Alberta, Edmonton, Alberta, Canada.
Transfusion. 2009 Jan;49(1):161-9. doi: 10.1111/j.1537-2995.2008.01937.x. Epub 2008 Oct 2.
Stromal cell-derived factor (SDF)-1, a chemokine produced in the bone marrow (BM), is essential for the homing of hematopoietic stem/progenitor cells (HSPCs) to the BM after transplantation. This study examines whether there is a correlation between the in vitro chemotaxis of CD34+ HSPC toward an SDF-1 gradient and in vivo hematopoietic engraftment.
Thirty-five patients underwent granulocyte-colony-stimulating factor HSPC collection and autologous transplant with a median dose of 7.7 (range, 3.9-41.5) x 10(6) CD34+ cells per kg body weight. The chemotactic index (CI) of CD34+ cells isolated from leukapheresis products collected from these patients was calculated as the ratio of the percentages of cells migrating toward an SDF-1 gradient to cells migrating to media alone. Expression of the SDF-1 receptor CXCR4 on CD34+ cells was measured by flow cytometry.
Spontaneous cell migration (range, 3.1 +/- 0.6 to 26.5 +/- 7.7%) and SDF-1-directed chemotaxis (11.1 +/- 0.7 to 54.9 +/- 8.3%) of CD34+ cells did not correlate with time to neutrophil engraftment, which occurred at a median of 10 days (range, 8-16 days). Nonparametric tests showed a negative correlation (r = -0.434) between CI and CD34+ cell dose such that neutrophil recovery occurred within the same period in patients transplanted with a lower dose of CD34+ cells but having a high CI as in those transplanted with a higher dose of CD34+ cells but having a low CI. Moreover, CI correlated (r = 0.8) with surface CXCR4 expression on CD34+ cells.
In patients transplanted with a relatively lower CD34+ cell dose who achieved fast engraftment, a higher responsiveness to SDF-1 and high CI could have compensated for the lower cell dose. However, to apply the CI as a prognostic factor of the rate of engraftment requires validation in a larger number of patients.
基质细胞衍生因子(SDF)-1是一种在骨髓(BM)中产生的趋化因子,对造血干细胞/祖细胞(HSPCs)移植后归巢至骨髓至关重要。本研究探讨CD34⁺ HSPCs对SDF-1梯度的体外趋化性与体内造血植入之间是否存在相关性。
35例患者接受粒细胞集落刺激因子动员的HSPC采集及自体移植,中位剂量为每千克体重7.7(范围3.9 - 41.5)×10⁶个CD34⁺细胞。从这些患者采集的白细胞分离产物中分离出的CD34⁺细胞的趋化指数(CI)计算为向SDF-1梯度迁移的细胞百分比与仅向培养基迁移的细胞百分比之比。通过流式细胞术检测CD34⁺细胞上SDF-1受体CXCR4的表达。
CD34⁺细胞的自发细胞迁移(范围3.1±0.6至26.5±7.7%)和SDF-1介导的趋化性(11.1±0.7至54.9±8.3%)与中性粒细胞植入时间无关,中性粒细胞植入中位时间为10天(范围8 - 16天)。非参数检验显示CI与CD34⁺细胞剂量之间呈负相关(r = -0.434),因此,接受较低剂量CD34⁺细胞但CI较高的患者与接受较高剂量CD34⁺细胞但CI较低的患者在同一时期实现中性粒细胞恢复。此外,CI与CD34⁺细胞表面CXCR4表达相关(r = 0.8)。
在接受相对较低剂量CD34⁺细胞移植且快速植入的患者中,对SDF-1的较高反应性和高CI可能弥补了较低的细胞剂量。然而,要将CI作为植入率的预后因素,需要在更多患者中进行验证。